ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

Summary

Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy. This will be an open label dose titration involving injections on 10 occasions, each two weeks apart. After dosing is complete there will be a 12 week follow up period. Blood samples will be drawn throughout the study to monitor safety and the body's response to the injections. Thyroid function will be measured throughout the trial to monitor Graves disease progression.

Timeline

Start

2016-09

Primary completion

2018-02-14

Completion

2018-02-14

Drugs

Indications